The Board of Directors at VIVO BIO TECH met on August 22, 2026, and approved the reappointment of three Whole-Time Directors. This includes Mr. Kalyan Ram Mangipudi, Mr. Sri Kalyan Kompella, and Dr. Sankaranarayanan Alangudi. Their reappointments are subject to shareholder approval and ensure continued leadership in crucial operational and strategic functions of the company for extended terms.
Board Meeting Outcome: Director Reappointments
VIVO BIO TECH Limited’s Board of Directors convened on Saturday, August 22, 2026. During this meeting, the Board inter-alia approved several key decisions, including the reappointment of three Whole-Time Directors. These appointments are vital for maintaining the company’s ongoing operations and strategic direction.
Key Reappointments Approved
The Board has approved the reappointment of:
- Mr. Kalyan Ram Mangipudi, who retires by rotation.
- Mr. Sri Kalyan Kompella (DIN: 03137506) for a period of five years, from November 03, 2026, until November 02, 2031.
- Dr. Sankaranarayanan Alangudi (DIN: 02703392) for a period of five years, from January 06, 2027, until January 05, 2032.
These reappointments are subject to the approval of the shareholders.
Annual General Meeting Scheduled
Furthermore, the Board announced that the 39th Annual General Meeting (AGM) of the Company will be held on Wednesday, September 30, 2026. The AGM will be conducted through Video Conferencing / Other Audio Visual Means (VC/OVAM).
Financial Reports Approved
In addition to the director reappointments, the Board also approved the Boards Report, Corporate Governance Report, and Management Discussion and Analysis report, along with all their annexures, for the financial year ended March 31, 2026.
Meeting Details
The Board meeting commenced at 07:16 p.m. and concluded at 07:31 p.m. on August 22, 2026.
Source: BSE
